BRAF激□抑製劑的全球市場:按藥物、適應症、分銷渠道、地區規模、份額、前景、機會分析2022-2028
市場調查報告書
商品編碼
1085723

BRAF激□抑製劑的全球市場:按藥物、適應症、分銷渠道、地區規模、份額、前景、機會分析2022-2028

BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 158 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球 BRAF 激□抑製劑市場的領先企業專注於獲得專利,並有望為新興市場的製造商創造更多機會。然而,市場的挑戰之一是患者的負擔。由於成本高昂,患者正在從實際治療方案轉向癌症治療的替代方案。

本報告研究和分析全球 BRAF 激□抑製劑市場,並提供有關市場驅動因素、抑製劑、市場機會、藥物/適應症/分銷渠道/區域市場分析和公司概況的信息。

目錄

第 1 章調查目標/先決條件

第二章市場概述

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
    • 市場細分:按藥物分類
    • 市場細分:按指示
    • 市場細分:按分銷渠道
    • 市場細分:按地區
  • 連貫的機會圖 (COM)

第三章市場動態、監管和趨勢分析

  • 促進因素
  • 抑制器
  • 市場機會
  • 影響分析
  • 產品發布
  • 主要發展
  • 監管場景
  • PEST 分析
  • 治療的演變
  • 管道分析
  • 兌換場景

第 4 章 COVID-19 對 BRAF 激□抑製劑市場的影響

  • 供給側和需求側分析
  • 整體影響
  • 對研發的影響

第 5 章全球 BRAF 激□抑製劑市場:按藥物分類(2017-2028 年(100 萬美元))

  • 簡介
  • 威羅非尼
  • 達拉非尼
  • Liphila phenib
  • 恩科拉非尼

第 6 章全球 BRAF 激□抑製劑市場:按適應症(2017-2028 年(100 萬美元))

  • 簡介
  • 轉移性黑色素瘤
  • 轉移性肺癌
  • 其他

第 7 章全球 BRAF 激□抑製劑市場:按分銷渠道(2017-2028 年(100 萬美元))

  • 簡介
  • 醫院藥房
  • 零售藥店
  • 網上藥店

第 8 章全球 BRAF 激□抑製劑市場:按地區劃分(2017-2028 年(100 萬美元))

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東
  • 非洲

第9章競爭態勢

  • 公司簡介
    • F. Hoffmann-La Roche AG
    • Novartis International AG
    • Pfizer, Inc.

第10章 章節

簡介目錄
Product Code: CMI4240

BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.

Market Dynamics

Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.

However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.

Key features of the study:

  • This report provides in-depth analysis of the global BRAF kinase inhibitors market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global BRAF kinase inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global BRAF Kinase Inhibitors Market, By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
  • Global BRAF Kinase Inhibitors Market, By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
  • Global BRAF Kinase Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global BRAF Kinase Inhibitors Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • F. Hoffmann-La Roche AG*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Novartis International AG
    • Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Product Launches
  • Key Developments
  • Regulatory Scenario
  • PEST Analysis
  • Treatment Evolution
  • Pipeline Analysis
  • Reimbursement Scenario

4. Impact of COVID-19 on BRAF Kinase Inhibitors Market

  • Supply Side And Demand Side Analysis
  • Overall Impact
  • Impact on Research and Development

5. Global BRAF Kinase Inhibitors Market, By Drug, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Vemurafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Dabrafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Lifirafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Encorafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global BRAF Kinase Inhibitors Market, By Indication, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Metastatic Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Metastatic Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global BRAF Kinase Inhibitors Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Company Profiles
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact